FDA
-
-
-
-
-
-
-
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program
-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Arcturus Therapeutics (ARCT)
-
-
-
-
-
-
-
Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress
-
-
-
-
-
-
-
Arcturus Therapeutics (ARCT) Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
-
-
-
-
-
-
-
Arcturus Therapeutics (ARCT) Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis
-
-
-
-
-
-
-
UPDATE: Citi Downgrades Arcturus Therapeutics (ARCT) to Neutral
-
-
-
-
-
-
-
Arcturus Therapeutics (ARCT) Granted FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in U.S.
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

